HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq lymphoma panel; HTG EdgeSeq microRNA whole-transcriptome assay; and HTG EdgeSeq DLBCL cell of origin assay. It also provides sample processing and molecular profiling of retrospective cohorts through its VERI/O laboratory; and designs custom panels for biopharmaceutical customers and research services, resulting from research and development collaboration agreements with biopharmaceutical customers. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company has a research collaboration with Insituto Valenciano de Oncologia on breast cancer recurrence risk. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HTGM
CUSIPN/A
Phone877-289-2615
Debt
Debt-to-Equity Ratio0.31
Current Ratio9.80
Quick Ratio9.59
Price-To-Earnings
Trailing P/E Ratio-1.95
Forward P/E Ratio-5.29
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.76 million
Price / Sales6.71
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-29.08
Profitability
EPS (Most Recent Fiscal Year)($1.79)
Net Income$-18,960,000.00
Net Margins-105.56%
Return on Equity-338.96%
Return on Assets-66.49%
Miscellaneous
Employees98
Outstanding Shares28,370,000
HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions
What is HTG Molecular Diagnostics' stock symbol?
HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."
How were HTG Molecular Diagnostics' earnings last quarter?
HTG Molecular Diagnostics Inc (NASDAQ:HTGM) released its earnings results on Thursday, May, 10th. The medical research company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.04. The medical research company earned $4.16 million during the quarter, compared to the consensus estimate of $5.24 million. HTG Molecular Diagnostics had a negative return on equity of 338.96% and a negative net margin of 105.56%. View HTG Molecular Diagnostics' Earnings History.
What price target have analysts set for HTGM?
2 brokerages have issued twelve-month target prices for HTG Molecular Diagnostics' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $7.00 in the next year. View Analyst Ratings for HTG Molecular Diagnostics.
Who are some of HTG Molecular Diagnostics' key competitors?
Who are HTG Molecular Diagnostics' key executives?
HTG Molecular Diagnostics' management team includes the folowing people:
- Mr. Timothy B. Johnson, CEO & Director (Age 57)
- Mr. John L. Lubniewski, Pres & COO (Age 54)
- Dr. Patrick C. Roche Ph.D., Sr. VP of Research & Product Devel. (Age 65)
- Mr. Shaun D. McMeans, VP of Fin. & Admin, Treasurer & CFO (Age 56)
- Dr. Debra A. Gordon Ph.D., J.D., VP, Chief Legal Counsel & Sec. (Age 58)
When did HTG Molecular Diagnostics IPO?
(HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Has HTG Molecular Diagnostics been receiving favorable news coverage?
Media headlines about HTGM stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a daily sentiment score of 0.18 on Accern's scale. They also gave news articles about the medical research company an impact score of 45.75 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are HTG Molecular Diagnostics' major shareholders?
HTG Molecular Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include EAM Global Investors LLC (0.67%), Stifel Financial Corp (0.33%), Northern Trust Corp (0.18%) and New York State Common Retirement Fund (0.17%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo, Plc Glaxosmithkline and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics.
Which institutional investors are buying HTG Molecular Diagnostics stock?
How do I buy shares of HTG Molecular Diagnostics?
Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HTG Molecular Diagnostics' stock price today?
One share of HTGM stock can currently be purchased for approximately $3.49.
How big of a company is HTG Molecular Diagnostics?
HTG Molecular Diagnostics has a market capitalization of $99.87 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.
How can I contact HTG Molecular Diagnostics?
HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.
MarketBeat Community Rating for HTG Molecular Diagnostics (HTGM)
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
